The side effects ‘ EPS ’ , ‘ parkinsonism ’ , and ‘ tremor ’ were significantly more common in children and adolescents treated with aripiprazole than in those treated with placebo .
Conclusion Our meta- analysis provides evidence for a non-negligible incidence of acute EPS in children and adolescents treated with aripiprazole .
Background Both the US FDA and the European Medicines Agency ( EMA ) have approved aripiprazole for use in adolescents for specific indications .
Given the assumed favorable side-effect profile of aripiprazole , its use in children and adolescents has increased for both official and off-label indications ( anxiety disorders , eating disorders , personality disorders ) .
However , several cases of children and adolescents with new-onset  extrapyramidal symptoms ( EPS )  after commencing treatment with aripiprazole have been reported , and a more systematic appraisal of this possible risk is lacking .
Objective We conducted a systematic review and a meta- analysis to assess the evidence for acute EPS ( acute dystonia , akathisia , Parkinsonism ) associated with the use of aripiprazole in children and adolescents .
Open label aripiprazole in the treatment of youth with tic disorders.
BACKGROUND Primarily safe and efficacious treatments for chronic tic disorders are needed . Also needed are such treatments that target co-morbid conditions . Aripiprazole , a dopaminergic/serotonergic agent with partial agonist properties at the D2 dopamine receptor and 5-hydrdoxytryptamine 1A ( 5-HT(1A ) ) receptor and antagonist properties at the 5-HT(2A ) receptor , holds promise in both regards . OBJECTIVE This was an open-label , flexible-dose study to evaluate the safety of aripiprazole in children and adolescents with a primary diagnosis of a chronic tic disorder with/without co-morbid disorder(s ) . METHOD Sixteen children ( 15 males ) aged 8 - 17 years participated in the 6-week trial . Ratings for tic , obsessive compulsive disorder ( OCD ) , attention-deficit/hyperactivity disorder ( ADHD ) , and side effects were administered weekly . Baseline and exit laboratory measures , electrocardiograms ( ECGs ) , weight , and height were obtained . RESULTS The average daily aripiprazole dose was 3.3 mg ( range 1.25 - 7.5 mg ) . Significant pre- and posttreatment differences were ascertained for the Yale Global Tic Severity Scale motor ( p < or = 0.0001 ) , phonic ( p < or = 0.0001 ) , and total tic ( p < or = 0.0001 ) scores . Results of other rating scales suggested significant improvements in co-morbid disorders as well , including OCD , ADHD , and depressive disorders . Although aripiprazole was well tolerated , increases in weight were found . CONCLUSION In this preliminary open-label trial , aripiprazole was a well-tolerated treatment for tics and co-morbid OCD and ADHD symptoms . Improvements in co-morbid conditions may be secondary to tic reduction or to specific to aripiprazole therapy ; however , further study is warranted
The side effects ‘ EPS ’ , ‘ parkinsonism ’ , and ‘ tremor ’ were significantly more common in children and adolescents treated with aripiprazole than in those treated with placebo .
Conclusion Our meta- analysis provides evidence for a non-negligible incidence of acute EPS in children and adolescents treated with aripiprazole .
Background Both the US FDA and the European Medicines Agency ( EMA ) have approved aripiprazole for use in adolescents for specific indications .
Given the assumed favorable side-effect profile of aripiprazole , its use in children and adolescents has increased for both official and off-label indications ( anxiety disorders , eating disorders , personality disorders ) .
However , several cases of children and adolescents with new-onset  extrapyramidal symptoms ( EPS )  after commencing treatment with aripiprazole have been reported , and a more systematic appraisal of this possible risk is lacking .
Objective We conducted a systematic review and a meta- analysis to assess the evidence for acute EPS ( acute dystonia , akathisia , Parkinsonism ) associated with the use of aripiprazole in children and adolescents .